Carcinomes bronchiques non à petites cellules (CBNPC) métastatiques, mutés ou réarrangés : comment déterminer la cible ?

Advances in molecular classification of non-small cell lung cancer have led to significant modifications of the treatment of these tumors. The molecular alterations are gene mutations (EGFR, KRAS, HER-2, BRAF) or gene rearrangements (ALK, ROS1, RET) which could be treated by targeted therapies, involving tools and methods appropriate to detect. This article describes issues related to the various samples for molecular analysis, the criteria for sample quality/selection, the different molecular techniques used with the perspective of available next generation sequencing and the reports of molecular testing.